Uwe Schoenbeck leads Pfizer’s Emerging Science & Innovation (ES&I) team. Part of the Worldwide Research, Development & Medical (WRDM) division, ES&I is charged with enhancing Pfizer’s pipeline through translation of external emerging science into breakthrough therapies for patients. The ES&I team constitutes an end-to-end ecosystem dedicated to the identification, evaluation and development of innovative science as well as providing a seamless range of partnering vehicles for academia, biotech and pharma partners globally.  Through outreach to the external research community via its dedicated Emerging Science Liaisons located around the globe, ES&I works to harness external breakthrough science, assets and technologies, leveraging a broad range of partnering vehicles, including research collaborations, consortia, licensing and acquisitions. With its Pfizer Innovation team, ES&I also enables early company formation through seed and equity investments. Its Target Science team is focused on novel target and biology discovery research to introduce differentiated programs with enhanced confidence in rationale into the WRDM portfolio. And through its Centers for Therapeutic Innovation (www.pfizercti.com), ES&I prosecutes breaking science sourced from leading academic and medical centers globally, working in close partnership with Principal Investigators to build an exciting pipeline across the range of Pfizer’s therapeutic interest areas. This fully integrated innovation capability aims to strengthen Pfizer’s research engine and provide key drivers for a pipeline of truly novel and differentiated first-in-class assets as well as breakthrough technologies by effectively combining external innovation with internal drug development capabilities.

Dr. Schoenbeck brings two decades of pharmaceutical drug development experience to Pfizer’s R&D executive leadership team. He is a member of Pfizer’s Senior Leadership Council and continues to serve on the Boards of Directors as well as Scientific Advisory Boards of biotech and academic institutions.  Prior to joining the company, he served as Vice President, Emerging R&D Innovation for Wyeth, and Vice President, Cardiovascular Research for Boehringer Ingelheim. Before joining industry, he held an Assistant Professor of Medicine position at Brigham & Women’s Hospital, Harvard Medical School.  He has served as a reviewer for multiple peer-reviewed journals and has published more than 100 peer-reviewed articles, review articles, book chapters and abstracts with particular contributions in molecular and cell biology, cardiovascular research, immunology, and metabolism.